ATC code L04
ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2] Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.[3]
| ATC codes |
|---|
| L Antineoplastic and immunomodulating agents |
| L01 Antineoplastic agents |
| L02 Endocrine therapy |
| L03 Immunostimulants |
| L04 Immunosuppressants |
|
|
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04.[4]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L04A Immunosuppressants
L04AA Selective immunosuppressants
- L04AA02 Muromonab-CD3
- L04AA03 Antilymphocyte immunoglobulin (horse)
- L04AA04 Antithymocyte immunoglobulin (rabbit)
- L04AA06 Mycophenolic acid
- L04AA10 Sirolimus
- L04AA13 Leflunomide
- L04AA15 Alefacept
- L04AA18 Everolimus
- L04AA19 Gusperimus
- L04AA21 Efalizumab
- L04AA22 Abetimus
- L04AA23 Natalizumab
- L04AA24 Abatacept
- L04AA25 Eculizumab
- L04AA26 Belimumab
- L04AA27 Fingolimod
- L04AA28 Belatacept
- L04AA29 Tofacitinib
- L04AA31 Teriflunomide
- L04AA32 Apremilast
- L04AA33 Vedolizumab
- L04AA34 Alemtuzumab
- L04AA35 Begelomab
- L04AA36 Ocrelizumab
- L04AA37 Baricitinib
- L04AA38 Ozanimod
- L04AA39 Emapalumab
- L04AA40 Cladribine
- L04AA41 Imlifidase
- L04AA42 Siponimod
- L04AA43 Ravulizumab
- L04AA44 Upadacitinib
L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
- L04AB01 Etanercept
- L04AB02 Infliximab
- L04AB03 Afelimomab
- L04AB04 Adalimumab
- L04AB05 Certolizumab pegol
- L04AB06 Golimumab
- L04AB07 Opinercept
L04AC Interleukin inhibitors
- L04AC01 Daclizumab
- L04AC02 Basiliximab
- L04AC03 Anakinra
- L04AC04 Rilonacept
- L04AC05 Ustekinumab
- L04AC07 Tocilizumab
- L04AC08 Canakinumab
- L04AC09 Briakinumab
- L04AC10 Secukinumab
- L04AC11 Siltuximab
- L04AC12 Brodalumab
- L04AC13 Ixekizumab
- L04AC14 Sarilumab
- L04AC15 Sirukumab
- L04AC16 Guselkumab
- L04AC17 Tildrakizumab
- L04AC18 Risankizumab
L04AD Calcineurin inhibitors
- L04AD01 Ciclosporin
- L04AD02 Tacrolimus
- L04AD03 Voclosporin
L04AX Other immunosuppressants
- L04AX01 Azathioprine
- L04AX02 Thalidomide
- L04AX03 Methotrexate
- L04AX04 Lenalidomide
- L04AX05 Pirfenidone
- L04AX06 Pomalidomide
- L04AX07 Dimethyl fumarate
- L04AX08 Darvadstrocel
gollark: - it funds the BBC, but you have to pay it if you watch *any* live TV, or watch BBC content online- it's per property, not per person, so if you have a license, and go somewhere without a license, and watch TV on some of your stuff, you are breaking the law (unless your thing is running entirely on battery power and not mains-connected?)- it costs about twice as much as online subscription service things- there are still black and white licenses which cost a third of the price
gollark: Very unrelated to anything, but I recently read about how TV licensing works in the UK and it's extremely weird.
gollark: "I support an increase in good things and a reduction in bad things"
gollark: Or maybe they just check it for keywords automatically, who knows.
gollark: I assume most people would agree with (most of) those things, but just saying, effectively, "more good things, fewer bad things" isn't very meaningful. Maybe that's what you're going for, but I assume they might want you to say/make up more personal-scale things.
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 2020-02-01.
- "ATC-Klassifikation mit definierten Tagesdosen DDD" (in German). German Institute for Medical Documentation and Information. Retrieved 2020-02-01.
- "ATC/DDD Index 2020: code L04". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2020: code QL04". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.